Monomethyl fumarate

Monomethyl fumarate
Clinical data
Trade names	Bafiertam
License data	US DailyMed: Monomethyl fumarate;
Routes of; administration	By mouth
ATC code	L04AX11 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name (2E)-4-methoxy-4-oxobut-2-enoic acid;
CAS Number	2756-87-8;
PubChem CID	5369209;
DrugBank	DB14219;
ChemSpider	4520322;
UNII	45IUB1PX8R;
KEGG	D11492;
ChEBI	CHEBI:167450;
ChEMBL	ChEMBL589586;
CompTox Dashboard (EPA)	DTXSID801016498 ;
ECHA InfoCard	100.018.557
Chemical and physical data
Formula	C5H6O4
Molar mass	130.099 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(=O)C=CC(=O)O;
	InChI InChI=1S/C5H6O4/c1-9-5(8)3-2-4(6)7/h2-3H,1H3,(H,6,7)/b3-2+; Key:NKHAVTQWNUWKEO-NSCUHMNNSA-N;

Monomethyl fumarate, sold under the brand name Bafiertam is a medication used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is taken by mouth.

The most common adverse reactions are flushing, abdominal pain, diarrhea, and nausea.

It was approved for medical use in the United States in April 2020.